hengrui glp-1 China Challenges Leaders, ㅤ, Kailera licensed a portfolio of obesity therapies from China's Jiangsu Hengrui, including a Phase 3 GLP-1 candidate that delivered up to 10.9% average weight loss at Hengrui Pharma and Kailera Therapeutics

"Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans"

Doctors evaluate health history, lifestyle, and body composition before recommending Trisculpt3D or any injectable protocol

Preliminary results from a study conducted with pregnant beef cows in late gestation reported increased maternal plasma MET concentrations in cows fed RPM and lower concentrations in those supplemented with GAA, with intermediate values in cows receiving both RPM + GAA (Motta et al., 2025), highlighting the role of GAA as a methyl consumer

This is followed by transformations and polymerization to the final product, pheomelanin